21 October 2017
News and Views
Links and Services
This week's New England Journal of Medicine evaluates daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1.
The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors